Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...

MicroRNAs

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Artemether and Euphorbia factor L9 suppress kynurenine production through distinct effects on tryptophan metabolism.

The Biochemical journal·2026

Same author

Malat1 regulates female Th2 cell cytokine expression through controlling early differentiation and response to IL-2.

Journal of immunology (Baltimore, Md. : 1950)·2025

Same author

Cdc48 plays a crucial role in redox homeostasis through dynamic reshaping of its interactome during early stationary phase.

Redox biology·2025

Same author

Upregulation of keratin 15 is required for varicella-zoster virus replication in keratinocytes and is attenuated in the live attenuated vOka vaccine strain.

Virology journal·2024

Same author

Long-read RNA sequencing of archival tissues reveals novel genes and transcripts associated with clear cell renal cell carcinoma recurrence and immune evasion.

Genome research·2024

Same author

Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis.

The Journal of clinical investigation·2024

Same journal

Limited evidence for evolutionarily conserved targeting of long non-coding RNAs by microRNAs.

Silence·2013

Same journal

Analysis of hairpin RNA transgene-induced gene silencing in Fusarium oxysporum.

Silence·2013

Same journal

cWords - systematic microRNA regulatory motif discovery from mRNA expression data.

Silence·2013

Same journal

Generation of a luciferase-based reporter for CHH and CG DNA methylation in Arabidopsis thaliana.

Silence·2013

Same journal

Strand-specific libraries for high throughput RNA sequencing (RNA-Seq) prepared without poly(A) selection.

Silence·2013

Same journal

MicroRNAs from the same precursor have different targeting properties.

Silence·2012

See all related articles

Search research articles

Related Experiment Video

Updated: May 29, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Noncoding RNAs and cancer.

Ohad Yogev¹, Dimitris Lagos

¹Cancer Research UK Viral Oncology Group, UCL Cancer Institute, University College London, Paul O'Gorman Building, 72 Huntley Street, London, WC1E 6BT, UK. o.yogev@ucl.ac.uk.

|October 1, 2011

Summary

This summary is machine-generated.

MicroRNAs (miRNAs) and noncoding RNAs are revolutionizing cancer research. This symposium explored their roles in gene regulation and cancer development, highlighting therapeutic potential.

More Related Videos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Related Experiment Videos

Last Updated: May 29, 2026

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Dual CRISPR-Interference Strategy for Targeting Synthetic Lethal Interactions Between Non-Coding RNAs in Cancer Cells

Published on: May 30, 2025

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube (SWCNT)-delivered MALAT1 Antisense Oligos

Published on: December 13, 2018

Area of Science:

Molecular Biology
Genetics
Oncology

Background:

Noncoding RNAs, including microRNAs (miRNAs), play crucial roles in gene expression regulation.
Dysregulation of noncoding RNAs is implicated in cancer development and progression.
The field of noncoding RNA research in cancer is rapidly expanding with significant therapeutic implications.

Purpose of the Study:

To discuss the function and regulation of noncoding RNAs in oncogenesis.
To highlight recent advances in the study of noncoding RNAs in cancer.
To foster collaboration and knowledge exchange among researchers in the field.

Main Methods:

The content is based on presentations and discussions from the 2011 Non-coding RNAs and Cancer Symposium.
Focus on functional studies and regulatory mechanisms of noncoding RNAs in cancer.
Review of current research and future directions.

Main Results:

Noncoding RNAs significantly influence gene expression pathways critical to cancer.
Specific miRNAs and other noncoding RNAs have been identified as key players in various oncogenic processes.
Emerging evidence points to the therapeutic potential of targeting noncoding RNAs in cancer treatment.

Conclusions:

Noncoding RNAs represent a vital area of cancer research with substantial therapeutic promise.
Continued investigation into the function and regulation of noncoding RNAs is essential for advancing cancer treatment strategies.
The symposium underscored the dynamic nature and growing importance of noncoding RNA research in oncology.